Mesoblast vs Arcus Biosciences
Arcus Biosciences is the larger business, with $247m of revenue in fiscal 2025 against $120m for Mesoblast (2.1 times as much). Mesoblast grew faster (599.2% against -4.3%). Mesoblast kept more of each dollar of sales as profit: a net margin of -47.8% against -142.9%. Arcus Biosciences carries less debt relative to equity (15.8% against 22.8%).
| Latest fiscal year | MesoblastMESO, 2026 | Arcus BiosciencesRCUS, 2025 |
|---|---|---|
| Revenue | $120m | $247m |
| Revenue growth | 599.2% | -4.3% |
| Net income | −$57.5m | −$353m |
| Operating margin | — | -156.3% |
| Net margin | -47.8% | -142.9% |
| Return on equity | -9.9% | -63.3% |
| Free cash flow | −$44.7m | −$484m |
| Cash | $103m | $222m |
| Total debt | $130m | $100m |
| Debt to equity | 22.8% | 15.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 601 |
| Market value | $1.91bn | $2.39bn |
| Price vs our value range | — | — |
| Moat score | — | 10 (Weak) |
| Insider trades, 12 months | 24 buys, 0 sales | 0 buys, 0 sales |